A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

May 31, 2031

Study Completion Date

May 31, 2031

Conditions
Multiple Myeloma
Interventions
DRUG

Dexamethasone

Infusion; Intravenous (IV), or Tablet; Oral

DRUG

Daratumumab

Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

DRUG

Venetoclax

Tablet; Oral

DRUG

Bortezomib

Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Trial Locations (40)

2010

The Kinghorn Cancer Centre /ID# 165431, Darlinghurst

2100

Rigshospitalet /ID# 164420, Copenhagen Ø

2217

St George Hospital /ID# 171063, Kogarah

3000

Peter MacCallum Cancer Ctr /ID# 164742, Melbourne

3065

St Vincent's Hospital Melbourne /ID# 165853, Fitzroy Melbourne

3128

Eastern Health /ID# 165850, Box Hill

5000

Duplicate_Royal Adelaide Hospital /ID# 171060, Adelaide

Odense University Hospital /ID# 164417, Odense

6000

Duplicate_Royal Perth Hospital /ID# 224895, Perth

7100

Sygehus Lillebalt, Vejle /ID# 164418, Vejle

8200

Duplicate_Aarhus University Hospital /ID# 164509, Aarhus N

14263

Duplicate_Roswell Park Comprehensive Cancer Center /ID# 169615, Buffalo

28203

Atrium Health Carolinas Medical Center /ID# 164948, Charlotte

30322

Winship Cancer Institute of Emory University /ID# 165427, Atlanta

37044

CHRU Tours - Hopital Bretonneau /ID# 164795, Tours

44000

Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 164767, Nantes

50937

University Hospital Cologne /ID# 166037, Cologne

75010

Duplicate_AP-HP - Hopital Saint-Louis /ID# 224758, Paris

79106

Universitaetsklinikum Freiburg /ID# 166036, Freiburg im Breisgau

80045

Univ of Colorado Cancer Center /ID# 167331, Aurora

86000

CHU Poitiers - La miletrie /ID# 164806, Poitiers

87042

CHU Limoges - Dupuytren 1 /ID# 224759, Limoges

94805

Institut Gustave Roussy /ID# 164807, Villejuif

97239

Oregon Health and Science University /ID# 166822, Portland

98109

University of Washington /ID# 164884, Seattle

33612-9416

Moffitt Cancer Center /ID# 169614, Tampa

60637-1443

The University of Chicago Medical Center /ID# 165429, Chicago

02215-5400

Beth Israel Deaconess Medical Center /ID# 210904, Boston

02215

Dana-Farber Cancer Institute /ID# 166886, Boston

07601

Hackensack Univ Med Ctr /ID# 225111, Hackensack

10021-4872

Weill Cornell Medicine/NYP /ID# 167605, New York

27710-3000

Duke Cancer Center /ID# 165104, Durham

27157-0001

Duplicate_Wake Forest Baptist Health /ID# 224447, Winston-Salem

T2N 5G2

Arthur J. E. Child Comprehensive Cancer Centre /ID# 167822, Calgary

T6G 1Z2

Cross Cancer Institute /ID# 203114, Edmonton

H4A 3J1

Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 167824, Montreal

467-8602

Nagoya City University Hospital /ID# 225273, Nagoya

296-8602

Kameda General Hospital /ID# 225246, Kamogawa-shi

790-8524

Duplicate_Matsuyama Red Cross Hospital /ID# 225196, Matsuyama

500-8323

Gifu Municipal Hospital /ID# 240381, Gifu

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

AbbVie

INDUSTRY